leisure time -WSS

leisure time

author：fashion 2025-09-30 01:01:39 - browse：74531

A display of TVs against an orange background. -- health policy coverage from STAT — Adobe

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a regulation that’s been 13 years in the making.

White House budget experts are reviewing changes to the regulation of broadcast drug advertisements that the Food and Drug Administration proposed in 2010, according to the Office of Management and Budget website. That proposal aimed to make commercials present drug risks in a manner that consumers notice and understand.

Drug ads have long been controversial. Aside from New Zealand, the United States is the only country that allows drug makers to advertise to consumers. Critics of drug ads say they pose consumer safety concerns by bombarding the public with promotions that distract viewers from potential side effects. Drug companies say commercials spark conversations between patients and doctors that promote clinically beneficial prescribing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Food makers tried to stack nutrition panel with preferred experts

focus

WSS

Change Healthcare payments predicted restored March 15

Change Healthcare payments predicted restored March 15

With psoriasis trial ahead, Alumis raises $259 million

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Amylyx ALS drug failure raises questions and concerns

Wikipedia

leisure time

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Telehealth for opioid use disorder is lifesaving

Dobbs anniversary: the lost opportunity of abortion as health care

Telehealth for opioid use disorder is lifesaving

Medical leaders decry Supreme Court decision on affirmative action

How to bring more disabled researchers into academia

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Malaria cases in Florida and Texas: Here’s what you need to know

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

hotspot

Amylyx ALS drug fails large clinical trial

Popular nasal decongestant doesn't actually relieve congestion

Acelyrin, a rare IPO success, stumbles in its first big test

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

How housing is health care on Long Island

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

entertainment

focus

focus

focus